Consistent with the unfavorable prognostic significance of UGT2B17 expression in CLL patients (above) (8, 9), high UGT2B17 expression was associated with enhanced proliferation by 1.7 (P < 0.05) and 2.0-fold (P < 0.01) for MEC1 and JVM2, respectively (Figures 1E,F). This evidence concerns the gene UGT2B17 and B-cell chronic lymphocytic leukemia.